Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor
- 15 November 2004
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 19 (2) , 1-22
- https://doi.org/10.1096/fj.04-2665fje
Abstract
Proapoptotic drugs such as docetaxel displayed least toxicity and highest antitumor efficacy following dosing during the circadian rest phase in mice, suggesting that cell cycle and apoptotic processes could be regulated by the circadian clock. In study 1, mouse bone marrow and/or tumor were obtained every 4 h for 24 h in C3H/HeN mice with or without MA13/C mammary adenocarcinoma in order to determine the circadian patterns in cell-cycle phase distribution and BCL-2 anti-apoptotic protein expression. In study 2, mouse bone marrow from B6D2F1 mice was sampled every 3 h for 24 h in order to confirm the BCL-2 rhythm and to study its relation with 24 h changes in the expression of proapoptotic BCL-2-associated X protein (BAX) protein and clock genes mPer2, mBmal1, mClock, and mTim mRNAs. The rhythms in G1-, S- or G2/M-phase cells were shifted in tumor compared with bone marrow. In the tumor, the mean proportion of G2/M-phase cells increased by 75% from late rest to late activity span (P from cosinor = 0.001). No 24 h rhythm was found for BCL-2 in tumors. In contrast to this, in the bone marrow, mean BCL-2 expression varied 2.8-fold in B6D2F1 mice (P=0.025) and 3- or 4.5-fold in tumor-bearing and nontumor-bearing C3H/HeN mice, with a peak during the early rest span (P=0.024 and P<0.001, respectively). BAX varied fivefold during the 24 h span with a major peak occurring near mid-activity (P=0.007). The mean mRNAs of mPer2, mClock, and mBmal1 varied twofold to threefold over the 24 h, with high values during the activity span (P<0.05). In the tumor, the circadian organization in cell-cycle phase distribution was shifted and BCL2 rhythm was ablated. Conversely, a molecular circadian clock likely regulated BCL-2 and BAX expression in the bone marrow, increasing cellular protection against apoptosis during the rest span.Keywords
Funding Information
- Institute of Cancer Research
- College of Natural Resources and Sciences, Humboldt State University
- Institut National de la Santé et de la Recherche Médicale
- Human Frontier Science Program
- Fondation pour la Recherche Médicale
- Association pour la Recherche sur le Cancer
This publication has 38 references indexed in Scilit:
- Cancer chronotherapy: Principles, applications, and perspectivesCancer, 2002
- Circadian chronotherapy for human cancersThe Lancet Oncology, 2001
- Circadian variation of cell proliferation and cell cycle protein expression in man: Clinical implicationsPublished by Springer Nature ,2000
- Variation in cell yield and proliferative activity of positive selected human CD34+ bone marrow cells along the circadian time scaleEuropean Journal of Haematology, 1998
- Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancerPublished by Elsevier ,1997
- A phase II trial of circadian-timed paclitaxel and cisplatin therapy in metastatic breast cancerAnnals of Oncology, 1997
- Circadian cell cycle variations of erythro‐ and myelopoiesis in humansEuropean Journal of Haematology, 1997
- 5-Fluorouracil (5-FU) induced apoptosis in gastric cancer cell lines: role of the p53 geneApoptosis, 1997
- Colony-forming unit-granulocyte-macrophage and DNA synthesis of human bone marrow are circadian stage-dependent and show covariationBlood, 1992
- Glutathione Content in Human Bone Marrow and Circadian Stage Relation to DNA SynthesisJNCI Journal of the National Cancer Institute, 1991